Anna Fateeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Fateeva has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Suzie Chen
Rutgers University
6 shared publications - Kevinn Eddy
Graduate Program in Cellular and Molecular Pharmacology, School of Graduate Studies, Rutgers University, Piscataway, NJ 08854, USA
5 shared publications - Mohamad Naser Eddin
Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA
3 shared publications - Allen B. Reitz
Fox Chase Therapeutics Discovery Inc
2 shared publications - Andrew Zloza
Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
2 shared publications - Ann W. Silk
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs. Significant progress has been made in the last few decades in melanoma therapeutics, most notably in targeted therapy and immunotherapy. These approaches have greatly improved treatment response outcomes; however, they remain limited in their abilities to hinder disease progression due, in part, to the onset of acquired resistance. In parallel, intrinsic resistance to therapy remains an issue to be resolved. In this review, we summarize currently available therapeutic options for melanoma treatment and focus on possible mechanisms that drive therapeutic resistance. A better understanding of therapy resistance will provide improved rational strategies to overcome these obstacles.
Top Cited PapersOpen AccessCurrent State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs. Significant progress has been made in the last few decades in melanoma therapeutics, most notably in targeted therapy and immunotherapy. These approaches have greatly improved treatment response outcomes; however, they remain limited in their abilities to hinder disease progression due, in part, to the onset of acquired resistance. In parallel, intrinsic resistance to therapy remains an issue to be resolved. In this review, we summarize currently available therapeutic options for melanoma treatment and focus on possible mechanisms that drive therapeutic resistance. A better understanding of therapy resistance will provide improved rational strategies to overcome these obstacles.
- Open Access
Study on the Complex Melanoma
Melanoma only accounts for about 1% of cases in skin cancer, unlike basal cell and/or squamous cell carcinomas; however, it owes its notoriety to being the deadliest type of skin cancer
Open AccessStudy on the Complex Melanoma
Melanoma only accounts for about 1% of cases in skin cancer, unlike basal cell and/or squamous cell carcinomas; however, it owes its notoriety to being the deadliest type of skin cancer
- Open Access
- 19 January 2024
- Published by Elsevier in JID Innovations
- Vol. 4 (2) , 100262
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
- 19 January 2024
- Published by Elsevier in JID Innovations
- Vol. 4 (2) , 100262
Open AccessAssessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
- Open Access
- 8 December 2023
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 37 (5) , 562-568
Overview of current melanoma therapies
Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.
- 8 December 2023
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 37 (5) , 562-568
Open AccessOverview of current melanoma therapies
Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.
- Open Access
- 28 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1293040
Editorial: The role of immunotherapy in melanomas
Editorial: The role of immunotherapy in melanomas
- 28 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1293040
Open AccessEditorial: The role of immunotherapy in melanomas
Editorial: The role of immunotherapy in melanomas
- Open Access
- 29 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2007-2018.e6
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study
- 29 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2007-2018.e6
Open AccessA Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study
- Open Access
Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression
Cancer is the second leading cause of death, and incidences are increasing globally. Simply defined, cancer is the uncontrolled proliferation of a cell, and depending on the tissue of origin, the cancer etiology, biology, progression, prognosis, and treatment will differ. Carcinogenesis and its progression are associated with genetic factors that can either be inherited and/or acquired and are classified as an oncogene or tumor suppressor. Many of these genetic factors converge on common signaling pathway(s), such as the MAPK and PI3K/AKT pathways. In this review, we will focus on the metabotropic glutamate receptor (mGluR) family, an upstream protein that transmits extracellular signals into the cell and has been shown to regulate many aspects of tumor development and progression. We explore the involvement of members of this receptor family in various cancers that include breast cancer, colorectal cancer, glioma, kidney cancer, melanoma, oral cancer, osteosarcoma, pancreatic cancer, prostate cancer, and T-cell cancers. Intriguingly, depending on the member, mGluRs can either be classified as oncogenes or tumor suppressors, although in general most act as an oncogene. The extensive work done to elucidate the role of mGluRs in various cancers suggests that it might be a viable strategy to therapeutically target glutamatergic signaling.
Open AccessImplications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression
Cancer is the second leading cause of death, and incidences are increasing globally. Simply defined, cancer is the uncontrolled proliferation of a cell, and depending on the tissue of origin, the cancer etiology, biology, progression, prognosis, and treatment will differ. Carcinogenesis and its progression are associated with genetic factors that can either be inherited and/or acquired and are classified as an oncogene or tumor suppressor. Many of these genetic factors converge on common signaling pathway(s), such as the MAPK and PI3K/AKT pathways. In this review, we will focus on the metabotropic glutamate receptor (mGluR) family, an upstream protein that transmits extracellular signals into the cell and has been shown to regulate many aspects of tumor development and progression. We explore the involvement of members of this receptor family in various cancers that include breast cancer, colorectal cancer, glioma, kidney cancer, melanoma, oral cancer, osteosarcoma, pancreatic cancer, prostate cancer, and T-cell cancers. Intriguingly, depending on the member, mGluRs can either be classified as oncogenes or tumor suppressors, although in general most act as an oncogene. The extensive work done to elucidate the role of mGluRs in various cancers suggests that it might be a viable strategy to therapeutically target glutamatergic signaling.